No Data
Tempest Therapeutics | 10-K/A: Annual report (Amendment)
H.C. Wainwright Maintains Tempest Therapeutics(TPST.US) With Hold Rating
Express News | Tempest Presents New Amezalpat MOA Data Supporting Its Potential as Novel Cancer Treatment At the 2025 AACR Annual Meeting
Tempest Therapeutics Announces FDA Granted ODD to TPST-1495
Express News | Tempest Therapeutics Inc - Data From Phase 2 Study Expected in 2026
Express News | Tempest Receives Orphan Drug Designation From the FDA for Tpst-1495 to Treat Patients With Fap
72953718 : it's staggering they are seemingly struggling to raise financing.